Navigation Links
Hemophilia Pipeline Overview - Once-a-week prophylaxis may soon become a reality
Date:12/13/2012

recombinant compounds can only gain significant market share by either addressing the lack of long-acting recombinant factor IX therapeutics or by addressing the need for more competitively priced recombinant products.

Economy of scale plays a role when producing a biologic compound cost-effectively and established companies will have an advantage in this area; having the right infrastructure, production facilities, marketing channels, and sales force are important factors that will determine whether a company can successfully enter the hemophilia market.

Datamonitor's up to date key pipeline hemophilia A and B therapeutics profiles includes the latest clinical data and industry developments.Understand the most pressing unmet needs in hemophilia and how current pipeline products can gain significant market share by addressing them.Compare pipeline products with current gold-standard treatments and assess what they will have to do to deliver growth.

OVERVIEW

Catalyst

Summary

Clinical Pipeline Overview

A handful of key players dominate the market

Gene therapy looks hopeful but market entry is still not predicted for this decade

Current Gold-Standard Product Profiles

Kogenate FS (FVIII recombinant; Bayer): the gold-standard hemophilia A therapy

BeneFIX (FIX recombinant; Pfizer): the gold-standard hemophilia B therapy

Target product profile versus current level of attainment

Key Factor VIII Pipeline Products

NN7008 (turoctocog alfa; Novo Nordisk)

BIIB 031 (rFVIIIFc; Biogen Idec)

NN7088 (rFVIII, glycopegylated; Novo Nordisk)

BAY-94-9027 (recombinant PEGylated factor VIII; Bayer)

Clinical and commercial attractiveness for key hemophilia A pipeline products

Key Factor IX Pipeline Products

BAX 326 (
'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novo Nordisk introduces HemaGo, a mobile application to track hemophilia treatment, bleeding episodes and life events
2. Bayers Second Annual Virtual Walk for Hemophilia Raises Funds, Generates Excitement in the Hemophilia Community
3. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
4. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
5. CSL Behring Receives FDA Orphan Drug Designation for rIX-FP, a Novel Therapy in Development to Treat Congenital Factor IX Deficiency (Hemophilia B)
6. Bausch + Lomb Product, Platform and Pipeline Innovations on Display at the Annual Meeting of the American Academy of Ophthalmology
7. Chronic Heart Failure (CHF) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
8. Neurostimulation Devices Market to 2018 - Technological Advances and Robust Pipeline with Multi-Indication Potential and Non-Invasive Therapies to Drive Growth
9. Epigenetics R&D Pipeline - Histone Deacetylases (HDACs) Offer the Most Promising Targets and Outnumber Other Classes of Epigenetic Targets
10. Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019
11. Biopsy Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 2015   Cynosure, Inc. (Nasdaq: ... devices for aesthetic procedures and precision surgical applications ... months ended June 30, 2015. "Our ... growth, as revenues increased 47 percent year-over-year and ... Officer Michael Davin. "While our international results reflected ...
(Date:7/28/2015)... CRY ), a leading medical device and tissue ... today its results for the second quarter and first ... Chairman, President and Chief Executive Officer, said, "During the ... with solid progress on several of our top organizational ... a direct sales model in France, advancing our strategic ...
(Date:7/28/2015)... July 28, 2015 ANI Pharmaceuticals, Inc. (NASDAQ: ... to release its second quarter and year-to-date 2015 financial ... of the U.S. financial markets. The earnings press release ... the Company,s website, www.anipharmaceuticals.com . ... and Charlotte C. Arnold , Vice President and ...
Breaking Medicine Technology:Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 2Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 3Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 4Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 5Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 6Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 7Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 8Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 9Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 10Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 11Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 12Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 13CryoLife Reports Second Quarter Financial Results 2CryoLife Reports Second Quarter Financial Results 3CryoLife Reports Second Quarter Financial Results 4CryoLife Reports Second Quarter Financial Results 5CryoLife Reports Second Quarter Financial Results 6CryoLife Reports Second Quarter Financial Results 7CryoLife Reports Second Quarter Financial Results 8CryoLife Reports Second Quarter Financial Results 9CryoLife Reports Second Quarter Financial Results 10CryoLife Reports Second Quarter Financial Results 11CryoLife Reports Second Quarter Financial Results 12CryoLife Reports Second Quarter Financial Results 13CryoLife Reports Second Quarter Financial Results 14ANI Pharmaceuticals Schedules Conference Call for Second Quarter and Year-to-Date 2015 Financial Results 2
... Aug. 1, 2011 Reportlinker.com announces that ... in its catalogue: Insulin- ... This package contains 14 ... European countries: Austria, Belgium, Denmark, Finland, France, ...
... Corporation announced today that 2011 year-to-date sales revenue rose ... continues the third year in a row for double-digit ... Oximeter product line was launched in 2008. ... is embracing the Spectros state-of-the-art broadband VLS tissue oximetry," ...
Cached Medicine Technology:Insulin- Western Europe 2Spectros Corporation Year-To-Date Oximeter Sales Revenue Up 51% in First Half of 2011 2
(Date:7/28/2015)... ... July 28, 2015 , ... Safeguard Scientifics, Inc. (NYSE:SFE) ... from time to time and depending on market conditions, to repurchase shares of ... Repurchases will be made in open market or privately negotiated transactions in compliance ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... services to include a proprietary, web based clinical knowledge system, called “Referral Guidance.” ... evidence based. It provides physicians who are anticipating making a subspecialty referral ...
(Date:7/28/2015)... GA (PRWEB) , ... July 28, 2015 , ... ... been chosen as a “Top Doctor 2015” by Atlanta Magazine. In Atlanta Magazine's annual ... row by hundreds of her esteemed colleagues and peers in the metro area as ...
(Date:7/28/2015)... , ... July 28, 2015 , ... A new study ... Easy Fibromyalgia, Study Says " sheds light on a possible new treatment option for ... two months of regular HBOT sessions, at least five per week, patients experienced a ...
(Date:7/28/2015)... Irvine, CA (PRWEB) , ... July 28, 2015 ... ... risk of Acute Coronary Syndromes (ACS-Heart Attack, Sudden Death, or Angina), many of ... clinical cardiology is the identification of individuals with active yet undetected sub-clinical disease, ...
Breaking Medicine News(10 mins):Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 3Health News:Introducing Care to Care’s New Web Based “Referral Guidance” Program 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 3Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 2Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 3Health News:Utility of a novel coronary artery disease biomarker algorithm in modifying physician adherence to guideline therapy presented at 20th World Congress on Heart Disease 2
... The following is a statement of Matthew L. ... http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO )The Campaign for Tobacco-Free ... his leadership role in Senate committee approval of ... Administration (FDA) regulatory authority over tobacco products, including ...
... a statement of Matthew L. Myers, President, Campaign ... ) The Campaign for Tobacco-Free Kids applauds ... role in Senate committee approval of legislation that ... regulatory authority over tobacco products, including the authority ...
... of Clinical Oncology. , ... Evanston, IL (Vocus) May 20, 2009 -- ... David J. Winchester , FACS, M.D., Chief of General Surgery and Surgical ... cancer has spread to the lymph nodes may not need a ...
... Alan B. Miller to Retain Chairman and CEO Positions Michael ... Pa., May 20 The Board of Directors of Universal ... nation,s largest hospital companies, today announced the election of Marc ... of Universal Health Service,s Chairman and Chief Executive, Alan Miller, ...
... On May 20, 2009, the US District Court for the ... AZN ) for an injunction barring Apotex (Apotex, ... AstraZeneca,s PULMICORT RESPULES (budesonide inhalation suspension) in the US. ... March 30, 2009, the US Food and Drug Administration granted ...
... SCHAUMBURG, Ill., May 20 Sagent Pharmaceuticals, Inc., ... it has raised $30 million in a second ... strategic investors. The round was again led by ... support upcoming product launches, development activities and strategic ...
Cached Medicine News:Health News:Sen. Jeff Merkley Votes to Protect America's Kids From Tobacco 2Health News:Sen. Jeff Merkley Votes to Protect America's Kids From Tobacco 3Health News:Sen. Tom Harkin Votes to Protect America's Kids From Tobacco 2Health News:Sen. Tom Harkin Votes to Protect America's Kids From Tobacco 3Health News:Breast Cancer Patients May be Spared Additional Surgery 2Health News:Breast Cancer Patients May be Spared Additional Surgery 3Health News:Universal Health Services, Inc. Announces Marc D. Miller Named President of Universal Health Services 2Health News:Court Grants AstraZeneca Preliminary Injunction Against Apotex in PULMICORT RESPULES Patent Litigation 2